Exploring Innovations in Muscle Wasting Disease Treatment
January 23, 2025 / The Clinical Trial Vanguard Executive Interviews In this interview, we engage with David Craig from Sarcomatrix Therapeutics to discuss the development of S-969, a novel oral small molecule targeting the Hippo-YAP pathway. Our conversation covers regulatory challenges, clinical trial design, manufacturing scale-up, intellectual property protection, and strategic partnerships, offering insights into […]
Sarcomatrix Therapeutics and Celito Tech Announce Strategic Collaboration to Advance S-969 to the Clinic
RENO, NV, UNITED STATES, January 07, 2025 – Sarcomatrix Therapeutics, a biotech innovator in muscle disease therapies, today announced a strategic collaboration with Celito Tech to leverage cutting-edge technology solutions for advancing Sarcomatrix’s lead oral drug candidate, S-969, into clinical trials. This partnership will harness the power of the CELITO’s Helyx Platform and expertise to […]
Sarcomatrix to Present at Three Major Events During JPM Week 2025 in San Francisco
RENO, NV, UNITED STATES, January 6, 2025 /EINPresswire.com/ — Reno, NV – January 6, 2025 – Sarcomatrix Therapeutics, a pioneering biotech company advancing innovative therapies for muscle diseases, is proud to announce its participation in three high-profile events during the upcoming JPM Week 2025 in San Francisco. These presentations highlight Sarcomatrix’s continued commitment to scientific excellence […]
Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as Chief of Technical Operations
RENO, NV, UNITED STATES, January 2, 2025 /EINPresswire.com/ — Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as Chief of Technical Operations Sarcomatrix Therapeutics, a biotechnology company focused on developing innovative treatments for muscle diseases, is pleased to announce the addition of Al Swarts as Chief of Technical Operations. This strategic hire underscores […]
Sarcomatrix Therapeutics AwardedPrestigious “Startup Spotlight” at BIO-Europe2024
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
Sarcomatrix Selected as One of 10 Companies to Present at Startup World Cup Regional, sponsored by Pegasus Tech Ventures
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
Sarcomatrix Advances Lead Compound S-969 to Large Animal Studies for Muscular Dystrophy
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
Understanding Sarcopenia: The Crucial Role of Declining α7β1 Integrin Expression in Aging Muscles.
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
How upregulating α7β1 integrin might compensate for the lack of dystrophin and DGC in individuals living with Duchenne or Beckers Muscular Dystrophy.
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
Sarcomatrix Therapeutics Corp.’s exclusive research Partner Strykagen Awarded SBIR Phase 2 Grant from the National Institutes of Health (NIH) to advance small molecules promoting muscle regeneration.
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.